Susquehanna International Group, LLP I Mab Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	BUY	$3.08 - $7.39 $20,944 - $50,252	6,800 Added 58.62%	18,400 $63,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $37,352 - $56,376	11,600 New	11,600 $48,000
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $367,422 - $1.38 Million	29,300 Added 623.4%	34,000 $552,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $1.34 Million - $2.2 Million	-29,500 Reduced 86.26%	4,700 $223,000
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $1.22 Million - $1.8 Million	21,300 Added 165.12%	34,200 $2.48 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $330,234 - $579,255	6,900 Added 115.0%	12,900 $1.08 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $266,280 - $383,820	6,000 New	6,000 $291,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $86.4M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.